We are pleased to share the final project report prepared by IPOPI, which highlights the objectives and achievements of the RECOMB consortium. Over the course of the project, partners worked closely together in a highly successful collaboration, and we are proud of what has been achieved. A major milestone of the project is the first-in-human, real-world experience showing that lentiviral RAG1-SCID gene therapy is effective, safe, and feasible within a multinational trial design.
RECOMB Project Final Report Highlights Advances in Gene Therapy for RAG1-SCID
Recomb is a multi-stakeholder research consortium aiming to advance a novel treatment for severe combined immunodeficiency (SCID) by conducting a clinical trial using gene therapy for one of the most common types of SCID: RAG1-SCID.
